Shots:

• The approval is based on a P-III study results assessing Eticovo vs the reference product (Enbrel) in 596 patients with rheumatoid arthritis across 70 sites in 10 countries
• The study resulted in ACR20 (80.8% vs 81.5%) for 52 wks. confirming results of 24 wks. study in (78.1% vs 80.3%)
• Eticovo (etanercept-ykro) is a biosimilar to Enbrel- a TNF blocker targeted for the treatment of rheumatoid arthritis- ankylosing spondylitis- plaque psoriasis- psoriatic arthritis and polyarticular juvenile idiopathic arthritis

Click here to read full press release/ article

 Ref: Samsung Bioepis | Image: Samsung Bioepis